Synergy Pharmaceuticals Inc  

(Public, NASDAQ:SGYP)   Watch this stock  
Find more results for SGYP
+0.10 (2.24%)
Mar 24 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 4.48 - 4.59
52 week 2.60 - 7.15
Open 4.50
Vol / Avg. 4.88M/6.07M
Mkt cap 1.04B
P/E     -
Div/yield     -
EPS -1.28
Shares 223.12M
Beta 1.48
Inst. own 53%
Feb 23, 2017
Q4 2016 Synergy Pharmaceuticals Inc Earnings Release (Estimated)
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '16) 2016
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -238.14% -193.03%
Return on average equity -968.35% -
Employees 116 -
CDP Score - -


420 Lexington Ave Rm 2012
NEW YORK, NY 10170-2099
United States - Map
+1-212-2970010 (Phone)
+1-212-2970019 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Synergy Pharmaceuticals Inc. (Synergy) is a biopharmaceutical company focused on the development and commercialization of gastrointestinal (GI) therapies. The Company's GI platform includes two lead product candidates: plecanatide and dolcanatide. It is engaged in the discovery, research and development involving uroguanylin analogs for the treatment of functional GI disorders and inflammatory bowel disease. Plecanatide is the Company's uroguanylin analog being evaluated for use as a once-daily tablet for two functional GI disorders, chronic idiopathic constipation (CIC) and irritable bowel syndrome with constipation (IBS-C). Plecanatide is a 16-amino acid peptide that is structurally identical to uroguanylin with the exception of a single amino acid change. Dolcanatide is also its uroguanylin analog being explored for inflammatory bowel disease (IBD). Dolcanatide is designed to be an analog of uroguanylin with resistance to standard digestive breakdown by proteases in the intestine.

Officers and directors

Gary S. Jacob Ph.D. Chairman of the Board, President, Chief Executive Officer
Age: 69
Bio & Compensation  - Reuters
Marino Garcia Executive Vice President and Chief Strategy Officer
Age: 49
Bio & Compensation  - Reuters
Patrick H. Griffin M.D. Executive Vice President and Chief Medical Officer
Age: 60
Bio & Compensation  - Reuters
Troy Hamilton Executive Vice President and Chief Commercial Officer
Age: 44
Bio & Compensation  - Reuters
Bernard F. Denoyer CPA Senior Vice President, Finance, Secretary
Age: 68
Bio & Compensation  - Reuters
Kunwar Shailubhai Ph.D. Chief Scientific Officer
Age: 57
Bio & Compensation  - Reuters
Thomas H. Adams Jr., Ph.D. Independent Director
Age: 73
Bio & Compensation  - Reuters
John P. Brancaccio Independent Director
Age: 68
Bio & Compensation  - Reuters
Timothy Callahan Independent Director
Age: 45
Bio & Compensation  - Reuters
Richard J. Daly Independent Director
Age: 55
Bio & Compensation  - Reuters